Mingfa Group (00846): The remaining two subsidiary companies in China have submitted applications for changes in their directors to the local regulatory authorities and are waiting for approval.
Mingfa Group (00846) has issued an announcement regarding the proposed restructuring of its subsidiary companies in China. The respective boards of directors of the companies have made recommendations on the matter, and a meeting will be held on... for further discussion.
MINGFA GROUP (00846) announced that the respective boards of directors of its Chinese subsidiaries have proposed a restructuring. As of the date of this announcement, the remaining two Chinese subsidiaries have submitted applications for changes in their directors to the local regulatory authorities and are awaiting approval. The proposed restructuring at the subsidiary level will be completed after the relevant approvals are obtained from the local authorities.
Related Articles

Zhi Xiang Jintai (688443.SH) has received approval for the clinical trial application of the research product GR2301 injection.

On September 17, FIH (02038) spent 1.07 million Hong Kong dollars to repurchase 65,000 shares.

Caitong: Policy relaxation and demand recovery driving the recovery of the Hong Kong real estate market, expected to usher in a new round of recovery cycle.
Zhi Xiang Jintai (688443.SH) has received approval for the clinical trial application of the research product GR2301 injection.

On September 17, FIH (02038) spent 1.07 million Hong Kong dollars to repurchase 65,000 shares.

Caitong: Policy relaxation and demand recovery driving the recovery of the Hong Kong real estate market, expected to usher in a new round of recovery cycle.
